Regulatory expectations across biosimilars, clinical trials, and clinical data transparency are evolving rapidly. In this TOPRA-sponsored webinar, tranScrip’s experts explored the key regulatory developments shaping the industry and the operational implications for sponsors navigating increasingly transparent regulatory frameworks
Biosimilar development is becoming more streamlined
Regulators are increasingly prioritising advanced analytical comparability and pharmacokinetic data, reducing reliance on large comparative efficacy studies in many biosimilar programmes.
Transparency planning is becoming essential
As publication and disclosure requirements continue to increase, sponsors are facing growing operational demands associated with redaction and clinical data publication.
UK Clinical Trial Regulations are evolving
The amended UK Clinical Trial Regulations introduce updated approval timelines, streamlined modification pathways, and strengthened transparency obligations.
Download the full webinar key takeaways report
Access the complete expert summary, including:
- six key regulatory takeaways
- practical implications for sponsors
- UK Clinical Trial Regulation updates
- biosimilar development considerations
- publication and redaction strategy insights
